The Role of Immune Semaphorins in Steatotic Liver Disease and Sepsis

Launched by UNIVERSITY HOSPITAL FOR INFECTIOUS DISEASES, CROATIA · Aug 27, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the role of certain proteins called semaphorins in patients with steatotic liver disease (a condition where fat builds up in the liver) who are also experiencing sepsis, a severe infection that spreads throughout the body. Researchers want to understand if having steatotic liver disease makes patients more likely to get infections and how this might affect their recovery from sepsis. By exploring the relationship between semaphorins and sepsis outcomes, the study hopes to find new insights that could improve treatment for these patients.

To participate in this trial, individuals must be between the ages of 65 and 74 and meet specific health criteria, such as showing signs of systemic inflammation and having a clinical suspicion of sepsis. They must be enrolled within 24 hours of being admitted to the hospital. Participants will undergo tests to help researchers gather data about their immune responses and health outcomes during their treatment for sepsis. This study is important as it aims to enhance our understanding of how liver disease interacts with serious infections, potentially leading to better care for patients facing these challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 2 or more SIRS (Systemic Inflammatory Response Syndrome) criteria (1. Hyperthermia \>38.3°C or Hypothermia \<36°C; 2. Tachycardia \>90 bpm; 3. Tachypnea \>20 bpm; 3. Leukocytosis (\>12,000 μL-1) or Leukopenia (\<4,000 μL-1))
• • clinical suspicion of sepsis
• • enrolled within 24 hours of hospital admission
• Exclusion Criteria:
• • no consent
• • immunosuppression
• • malignancies
• • immune diseases
• • pregnancy
• • HIV infection
• • presence of chronic liver disease
• • consumption of alcohol \> 20 g/day